A single dose of the COVID-19 monoclonal antibody therapy developing Regeneron reduced the risk of contracting the virus by around 82% for up to eight months, according to new trial data.

Clinical trials show that monoclonal antibody treatment, actually a combination of two antibodies, reduces COVID-19 related ... and Chief Scientific Officer for Regeneron Pharmaceuticals, to ...

Certain antiviral and mAb therapies were shown to lower mortality and hospitalization rates in those infected with SARS-CoV-2 Omicron variants.

The inhaled monoclonal antibody IN-006 shows promise in COVID-19 treatment, with high airway antibody levels and a favorable safety profile in healthy adults.

Just a few months after Vir Biotechnology lost an emergency authorization for its COVID-19 antibody, Marianne de Backer ...

One month later, the FDA authorized using the drug to treat COVID-19 in high-risk patients (such as people with diabetes or asthma) who have mild to moderate disease. In January, Regeneron announced ...

Valued at a market cap of $82.9 billion, Regeneron Pharmaceuticals ... and is also known for developing an antibody cocktail for COVID-19, called REGEN-COV. Companies valued at $10 billion ...

As head of infectious disease research at Regeneron, the Tarrytown, N.Y.-based biotech firm with $7.9 billion in annual revenue, Kyratsous is leading one of pharma’s most watched—and in the ...

US FDA revokes authorization for four COVID antibody drugs Healthcare & Pharmaceuticalscategory· December 23, 2024 Regeneron Pharmaceuticals has settled allegations that it misused a patented ...